Drug Trial Radar · NCT06527365
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 8, 2024
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Veradermics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.
Conditions
- Androgenetic Alopecia
- AGA
- Male Pattern Baldness
Interventions
VDPHL01Drug
VDPHL01 Extended Release (ER) Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in non-vellus Total Area Hair Count (TAHC)Time frame: Month 12
- Subjects Evaluation of Treatment BenefitTime frame: Month 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
01
San Diego, California
04
New Albany, Indiana
03
Hackensack, New Jersey
02
South Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.